rAvPAL-PEG

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Phenylketonuria

Conditions

Phenylketonuria

Trial Timeline

Mar 1, 2011 → Apr 1, 2015

NCT ID

NCT01212744

About rAvPAL-PEG

rAvPAL-PEG is a phase 2 stage product being developed by BioMarin Pharmaceutical for Phenylketonuria. The current trial status is completed. This product is registered under clinical trial identifier NCT01212744. Target conditions include Phenylketonuria.

What happened to similar drugs?

7 of 20 similar drugs in Phenylketonuria were approved

Approved (7) Terminated (1) Active (12)

❌SYNB1934v1 + PlaceboSynlogicPhase 3

🔄Kuvan®MerckPhase 3

✅Kuvan®MerckApproved

🔄Sapropterin dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3

🔄BMN165 20mg/day + BMN165 40mg/day + PlaceboBioMarin PharmaceuticalPhase 3

🔄sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3

✅saproterin dihydrochlorideBioMarin PharmaceuticalApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01212744	Phase 2	Completed	Mar 1, 2011	Apr 1, 2015	Phenylketonuria
NCT00924703	Phase 2	Completed	Jan 13, 2010	Jan 31, 2019	Phenylketonuria
NCT00634660	Phase 1	Completed	May 1, 2008	Oct 1, 2009	Phenylketonuria

Competing Products

20 competing products in Phenylketonuria

See all competitors

Product	Company	Stage	Hype Score
mRNA-3210	Moderna	Phase 2	0
SYNB1934v1 + Placebo	Synlogic	Phase 3	22
SYNB1618 + Placebo	Synlogic	Phase 1/2	22
SYNB1618 + SYNB1934	Synlogic	Phase 2	25
Kuvan®	Merck	Phase 3	40
Kuvan®	Merck	Approved	43
SAR444836	Sanofi	Phase 1/2	36
Kuvan	BioMarin Pharmaceutical	Pre-clinical	15
rAvPAL-PEG	BioMarin Pharmaceutical	Phase 2	32
Sapropterin (Kuvan)	BioMarin Pharmaceutical	Pre-clinical	23
BMN 165 (rAvPAL-PEG)	BioMarin Pharmaceutical	Phase 2	32
BMN 307	BioMarin Pharmaceutical	Phase 1/2	33
Sapropterin	BioMarin Pharmaceutical	Pre-clinical	23
Sapropterin dihydrochloride + Placebo	BioMarin Pharmaceutical	Phase 3	37
BMN165 20mg/day + BMN165 40mg/day + Placebo	BioMarin Pharmaceutical	Phase 3	37
sapropterin dihydrochloride	BioMarin Pharmaceutical	Phase 3	37
saproterin dihydrochloride	BioMarin Pharmaceutical	Approved	40
sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placebo	BioMarin Pharmaceutical	Phase 1	26
Pegvaliase	BioMarin Pharmaceutical	Pre-clinical	30
Pegvaliase	BioMarin Pharmaceutical	Pre-clinical	23